Updated Jul 16, 2026
Looker Benjamin has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $77K.
Benjamin Looker serves as the General Counsel at Esperion Therapeutics, Inc., a pharmaceutical company focused on developing non-statin medicines for cholesterol management. He has been involved in the company through various SEC filings, indicating his role in legal and compliance matters.
| Role | Chief Legal Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-13 | ESPR | Esperion Therapeutics, Inc. | D — Derivative transaction | 667.5K | — | |
| 2026-06-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 11.8K | $3.15 | $37K |
| 2026-03-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 5.7K | $2.70 | $15K |
| 2026-03-16 | ESPR | Esperion Therapeutics, Inc. | A — Grant or award | 300.8K | $0.00 | |
| 2026-01-21 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 1.7K | $2.88 | $5K |
| 2025-09-17 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 6.3K | $2.80 | $18K |
| 2025-07-17 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 1.3K | $1.13 | $1K |
Benjamin Looker serves as the General Counsel at Esperion Therapeutics, Inc., a pharmaceutical company focused on developing non-statin medicines for cholesterol management. He has been involved in the company through various SEC filings, indicating his role in legal and compliance matters.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($77K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Looker Benjamin profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.